Oliver Worsley

Head shot of Oliver Worsely
Oliver Worsley

Oliver Worsley is a freelance journalist and has contributed over 100 weekly articles to FierceBiotech for over the duration of a year now. Oliver is a graduate from the University of Edinburgh and is currently pursuing a PhD at the Genome Institute of Singapore. He is an enthusiastic outdoorsman having completed multiple Ironman triathlons and adventure races.   

Stories by Oliver Worsley

breast cancer

PARP inhibitor plus epigenetic inhibitor reduces cancer growth and survival

Poly(ADP-ribose) polymerase inhibitors (PARPis) are an exciting class of cancer drugs currently used in the clinic. To date, however, patients with acute myeloid leukemia--a cancer with a notoriously poor outcome after diagnosis--have failed to respond to them. Scientists have recently shown that combining PARPis with an epigenetic modifier significantly reduces cancer growth and survival of leukemia cells.